| Literature DB >> 34624099 |
Michelle Jeong1,2, Binu Singh1, Olivia A Wackowski1,2, Rohit Mukherjee1, Michael B Steinberg1,3, Cristine D Delnevo1,2.
Abstract
INTRODUCTION: News media can shape public perceptions about e-cigarettes, particularly in the context of ongoing uncertainty from the recent outbreak of e-cigarette or vaping product use-associated lung injury (EVALI). This study aimed to characterize news articles published about e-cigarettes in 2019, including before and during the EVALI outbreak. AIMS AND METHODS: Using 24 e-cigarette-related search terms, we gathered all articles published in leading print and online U.S. news sources in 2019 from databases (i.e., Factiva, Access World News) and archival web sites (i.e., www.newspapers.com). We conducted a content analysis of e-cigarette themes and statements, identifying differences in themes between articles that did and did not mention EVALI.Entities:
Mesh:
Year: 2022 PMID: 34624099 PMCID: PMC8962717 DOI: 10.1093/ntr/ntab203
Source DB: PubMed Journal: Nicotine Tob Res ISSN: 1462-2203 Impact factor: 5.825
Figure 1.EVALI-related articles by month. Line graphs indicate EVALI-specific content only coded among EVALI-related articles. Note: In September 2019, CDC issued recommendations to broadly “refrain from using e-cigarette/vaping products, especially those with THC.” In December 2019, CDC refined their recommendations to “not use e-cigarette, or vaping, products that contain THC” specifically.
Prevalence of E-cigarette Themes and Topics
| All articles | EVALI articles | Non-EVALI articles | p | |
|---|---|---|---|---|
|
|
|
| ||
|
| ||||
| News/feature | 1505 (91.6) | 940 (92.6) | 565 (90.0) | .061 |
| Op-Ed | 137 (8.3) | 75 (7.4) | 62 (9.9) | .077 |
|
| ||||
| Policy/regulation | 736 (44.8) | 412 (40.6) | 324 (51.6) | <.001 |
| Health effects | 577 (35.1) | 485 (47.8) | 92 (14.6) | <.001 |
| Industry activities/retail | 129 (7.8) | 50 (4.9) | 79 (12.6) | <.001 |
| Prevalence/trends | 112 (6.8) | 30 (3.0) | 82 (13.1) | <.001 |
| Cessation | 40 (2.4) | 14 (1.4) | 26 (4.1) | <.001 |
| Other | 49 (3.0) | 24 (2.4) | 25 (4.0) | .061 |
|
| ||||
| Youth prevalence | 793 (48.3) | 401 (39.5) | 392 (62.4) | <.001 |
| Mentions JUUL | 661 (40.2) | 331 (32.6) | 330 (52.5) | <.001 |
| Flavors appeal to youth | 448 (27.3) | 270 (26.6) | 178 (28.3) | .441 |
| Encourage youth use/gateway | 251 (15.3) | 92 (9.1) | 159 (25.3) | <.001 |
|
| ||||
| Flavors | 466 (28.4) | 255 (25.1) | 211 (33.6) | <.001 |
| Nicotine content | 100 (6.1) | 31 (3.1) | 69 (11.0) | <.001 |
|
| ||||
| Flavor bans | 722 (43.9) | 477 (47.0) | 245 (39.0) | .002 |
| Marketing/advertising restrictions | 417 (25.4) | 265 (26.1) | 152 (24.2) | .389 |
| Age-of-sale restrictions | 384 (23.4) | 172 (16.9) | 212 (33.8) | <.001 |
| FDA regulation | 381 (23.2) | 178 (17.5) | 203 (32.3) | <.001 |
| Smoke free air laws | 102 (6.2) | 45 (4.4) | 57 (9.1) | <.001 |
| Taxation | 99 (6.0) | 51 (5.0) | 48 (7.6) | .03 |
| Warning labels | 47 (2.9) | 21 (2.1) | 26 (4.1) | .014 |
|
| ||||
| Nicotine is addictive/harmful | 516 (31.4) | 265 (26.1) | 251(40.0) | <.001 |
| Quality concerns about manufacturing | 356 (21.7) | 329 (32.4) | 27 (4.3) | <.001 |
| Exposure to toxins/carcinogens | 209 (12.7) | 138 (13.6) | 71 (11.3) | .176 |
| Health effects unknown | 189 (11.5) | 109 (10.7) | 80 (12.7) | .217 |
| Not effective for cessation | 43 (2.6) | 10 (1.0) | 33 (5.3) | <.001 |
| Prevents quitting | 14 (0.9) | 2 (0.2) | 12 (1.9) | <.001 |
|
| ||||
| Less risky than cigarettes | 337 (20.5) | 186 (18.3) | 151 (24.0) | .005 |
| Effective tool for cessation | 333 (20.3) | 174 (17.1) | 159 (25.3) | <.001 |
|
| ||||
| Vaping THC | 669 (65.9) | |||
| Mentioned in first half of article | – | 462 (45.5) | – | – |
| Mentioned in second half of article | – | 207 (20.3) | – | – |
| Death related to vaping | – | 821 (80.9) | – | – |
| FDA/CDC recommendation | – | 222 (21.9) | – | – |
p-Values indicate significance levels for differences between EVALI and non-EVALI articles.
aEVALI-specific content was only present and coded for in articles that mentioned EVALI.